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REVIEW CURRENTOPINION Preservation of muscle mass as a strategy to
reduce the toxic effects of cancer chemotherapy
on body compositionwww.supportiveandpalliativecaa b,c,d a,b,c,d,e,fFabrizio Pin , Marion E. Couch , and Andrea BonettoPurpose of review
Cancer patients undergoing chemotherapy often experience very debilitating side effects, including
unintentional weight loss, nausea, and vomiting. Changes in body composition, specifically lean body
mass (LBM), are known to have important implications for anticancer drug toxicity and cancer prognosis.
Currently, chemotherapy dosing is based on calculation of body surface area, although this approximation
does not take into consideration the variability in lean and adipose tissue mass.
Recent findings
Patients with depletion of muscle mass present higher chemotherapy-related toxicity, whereas patients with
larger amounts of LBM show fewer toxicities and better outcomes. Commonly used chemotherapy regimens
promote changes in body composition, primarily by affecting skeletal muscle, as well as fat and bone mass.
Experimental evidence has shown that pro-atrophy mechanisms, abnormal mitochondrial metabolism, and
reduced protein anabolism are primarily implicated in muscle depletion. Muscle-targeted pro-anabolic strategies
have proven successful in preserving lean tissue in the occurrence of cancer or following chemotherapy.
Summary
Muscle wasting often occurs as a consequence of anticancer treatments and is indicative of worse
outcomes and poor quality of life in cancer patients. Accurate assessment of body composition and
preservation of muscle mass may reduce chemotherapy toxicity and improve the overall survival.
Keywords
body composition, cachexia, chemotherapy, skeletal muscleINTRODUCTION CHEMOTHERAPY NEGATIVELY IMPACTSaDepartment of Anatomy and Cell Biology, bDepartment of Otolaryngol-
ogy – Head & Neck Surgery, cCenter for Cachexia Research Innovation
and Therapy, dSimon Cancer Center, eDepartment of Surgery and
fIndiana Center for Musculoskeletal Health, Indiana University School
of Medicine, Indianapolis, Indiana, USA
Correspondence to Andrea Bonetto, PhD, Department of Surgery, Indiana
University School of Medicine, 980WWalnut Street, R3-C522 Indianapolis,
IN 46202, USA. Tel: +1 317 278 0302; e-mail: abonetto@iu.edu
Curr Opin Support Palliat Care 2018, 12:420–426
DOI:10.1097/SPC.0000000000000382
This is an open access article distributed under the terms of the Creative
Commons Attribution-Non Commercial-No Derivatives License 4.0
(CCBY-NC-ND), where it is permissible to download and share the work
provided it is properly cited. The work cannot be changed in any way or
used commercially without permission from the journal.Despite significant progress in the development of
novel cancer treatments, chemotherapy is often
utilized for most tumors irrespective of its associated
toxicities [1]. It is now clear that chemotherapy
plays a direct role in the loss of muscle mass and
muscle strength in cancer patients (often referred to
as ‘cachexia’), a condition that can persist for
months to years following remission [2–9]. Notably,
patients suffering from cachexia-related symptoms
are often unable to complete treatment regimens
and may require delays in treatment, dose limita-
tion, or discontinuation of therapy [10,11]. Several
studies have been conducted with the goal of iden-
tifying strategies to minimize or prevent cancer
therapy toxicities [12]. This review will highlight
the mechanistic effects of cancer treatments on
body composition and provide potential strategies
proposed to limit chemotherapy-related toxicities in
cancer patients, including ways to preserve lean
body mass (LBM).re.comPHYSICAL FUNCTION BY CAUSING
IMPAIRED MUSCLE FUNCTION
Chemotherapeutic agents act primarily by antago-
nizing essential mechanisms of cell division. These
antiproliferative and cytotoxic drugs have a highVolume 12  Number 4  December 2018
KEY POINTS
 Anticancer treatments severely affect body composition,
primarily by causing muscle depletion, as well as loss
of adipose tissues and bone mass.
 Muscle wasting following administration of
chemotherapy strongly affects the quality of life,
leading to fatigue and reduced physical function, and
predicts poor survival among cancer patients.
 Accurate assessment of body composition and
preservation of skeletal muscle mass represent powerful
tools to reduce chemotherapy toxicity.
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but at the same time are responsible for dramatic
toxicities in the host body. Among these side effects,
nausea, vomiting, diarrhea, anorexia, body weight
changes, and anemia are the most relevant [13].
Notably, muscle weakness and fatigue are some of
the most common and distressing symptoms associ-
ated with cancer and chemotherapy [14,15], and it is
estimated that over 70% of patients receiving cancer
treatments will present symptoms associated with
these conditions [16,17,18
&&
,19,20]. Because of this,
chemotherapy-dependent effects on body composi-
tion and on musculoskeletal function have recently
become subject of interest [3]. Indeed, muscle dys-
function in cancer patients may affect the overall
quality of life, including productivity and physical
functioning, and this may be further intensified fol-
lowing chemotherapy [21–27]. In this regard, it has
been shown that administration of chemotherapy
promotes depletion of skeletal muscle mass in
patients affected with advanced tumors, including
lung, breast, colorectal, prostate, and nonsmall-cell
lung (NSCLC) cancers, and this condition negatively
impacts physical function by causing impaired mus-
cle strength (such as slower chair-rise time and
reducedhand-grip force), as well as joint dysfunction
[2–4,18
&&
,28
&
,29]. Unfortunately, no treatments are
currently available to relieve such conditions.PROPER ASSESSMENT OF BODY
COMPOSITION IS ESSENTIAL TO
PREVENT CHEMOTHERAPY TOXICITY
Experimental and clinical findings suggest that
body composition and, in particular, skeletalmuscle
mass play a pivotal role in the response to chemo-
therapy and in the prevention of its associated
toxicities, as well as in ultimately predicting out-
comes and survival of cancer patients. For instance,
Du Bois and Du Bois [30] proposed a method to
estimate pharmacokinetics and dosage of a drug by1751-4258 Copyright  2018 The Author(s). Published by Wolters Kluwedetermining the body surface area (BSA) as a relation
between height and weight, according to the for-
mula BSA (m2)¼ ([height (cm2)weight (kg)]/
3600)1/2. Although not optimal, this method is still
widely used, especially for dosing of drugs charac-
terized by a low therapeutic index, as in the case of
chemotherapeutics, and several modifications were
suggested to generate a better approximation of the
BSA [31,32].
There remains, however, a potential limitation
associated with this dosing method in that it does
not take into account the considerable variation in
BSA because of changes in fat mass. Indeed, it has
been previously demonstrated that the assessment
of BSA can overestimate or underestimate the cor-
rect drug dosing. This is particularly true for anti-
neoplastic agents, most of which have a narrow
therapeutic window, thus leading to low efficacy
in case of underdosing or severe side effects in case of
overdosing [33]. Along the same line, Chatelut et al.
[34] provided evidence that the clearance of differ-
ent chemotherapeutic agents often poorly correlate
with the BSA, thus casting doubt on the effective-
ness of this parameter for the dosing of chemother-
apy. Another study by Prado et al. [35] also showed
that cancer patients presenting with identical BSA
may regardless show high variability in LBM, pri-
marily because of significant changes in adipose
tissue mass. These findings suggest that accurate
body composition assessment is linked to chemo-
therapy toxicity and survival. Therefore, wasting of
skeletal muscle mass, by constituting a smaller vol-
ume of distribution for anticancer drugs, may also
lead to inadvertent overdosing and exacerbated tox-
icity. This hypothesis was further supported bymore
recent evidence showing that patients with low
amount of lean tissue at time of cancer diagnosis
were also more susceptible to develop side effects
following chemotherapy administration [36]. Addi-
tionally, the prevalence of dose-limiting toxicities
was also shown in a cohort of advanced renal cell
carcinoma patients presenting muscle depletion
and low lean tissue mass with respect to patients
not affected by these conditions [37].
In order to address the concerns related to the use
ofBSAforchemotherapydosing, alternativemethods
have been proposed, including the assessment of the
ideal bodyweight or the BMI (i.e. weight adjusted for
stature, kg/m2).However, all theseweight-basedmet-
rics do not take into account bodymass composition
and therelativeproportionsanddistributionsof lean,
fat and bone mass in the human body [38,39]. As
body composition in cancer patients may result
highly variable in terms of muscle and fat mass, as
well as of distribution of adipose tissue between
abdominal and subcutaneous compartments, theser Health, Inc. www.supportiveandpalliativecare.com 421
Cachexia, nutrition and hydrationfactors are likely critical to effectively establish che-
motherapy dosing [40
&&
,41]. This is of particular
importance in patients with ‘sarcopenic obesity,’ a
conditiondescribing individuals that simultaneously
present with high fat mass and low muscularity
resulting in increased risk for adverse outcomes in
the occurrence of cancer [42,43].
Enhanced treatment-associated toxicity and
increasedmortality inpatients affectedwithdifferent
types of cancer have been shown to directly correlate
with changes in body composition, primarilymuscle
mass, and there is also evidence that the amount of
adipose tissue may represent a useful predictor of
outcomes. Indeed, data generated in patients with
metastatic colorectal cancer (mCRC) receiving bev-
acizumab suggested that low visceral adipose tissue
correlates with shorter survival and overall negative
outcomes [44]. Sarcopenia is also an indicator of poor
outcomes and greater toxicity in patients with non-
metastatic [45] and resectable stage I–III colorectal
tumors [46], or in patients affected with mCRC and
receiving palliative chemotherapy [47
&
]. Loss of skel-
etal muscle or changes in skeletal muscle density
(SMD) following systemic chemotherapy treatments
were associated with poor survival in patients
affected with diffuse large B-cell lymphoma [48], as
well as foregut [49] and ovarian [50] cancers. Analo-
gously, in a study conducted on lung cancer patients,
chemotherapy treatment preceded the detection of
decreased muscle mass and increased adipose tissue.
In this context, sarcopenia was correlated with
reduced tolerance to chemotherapy treatment and
thought to predict a worse prognosis [51].
As expected, a retrospective analysis of advanced
nonsquamous NSCLC patients who received plati-
num-based therapy in combination with bevacizu-
mab demonstrated that weight gain during or after
treatment is a reliable indicator of clinical benefit
and improved survival [52]. In a retrospective study
including 193 patients affected with unresectable
pancreatic cancer showing significant loss of adi-
pose tissue following administration of neoadjuvant
treatment, gain in muscle mass was associated with
increased chance of resectability and better out-
comes [53
&
]. Together these findings indicate that
proper assessment of body composition is an impor-
tant factor to consider for the prevention of
chemotherapy toxicity.ANTI-CANCER DRUGS ARE ASSOCIATED
WITH MUSCULOSKELETAL
DYSFUNCTIONS
Preclinical investigations support a relationship
between chemotherapy treatment and the loss of
body weight, constituting both LBM and adipose422 www.supportiveandpalliativecare.comtissue (i.e. cachexia) occurring in the majority of
cancer patients. Le Bricon and colleagues were
among the first to provide evidence of a link
between the administration of chemotherapeutics
[such as cyclophosphamide, 5-fluorouracil (5-FU),
cisplatin, or methotrexate] and abnormal nitrogen
balance in the muscle of tumor-bearing rats leading
to significant loss of skeletal muscle mass. Notably,
these drug-associated toxicities were exacerbated in
the cancer hosts, despite the fact that tumor prolif-
eration was effectively counteracted [54].
Further, several investigators provided the first
mechanistic explanation for the loss of muscle mass
observed in tumor hosts exposed to chemothera-
peutics. On the basis of these findings, anticancer
drugs (including cisplatin, irinotecan, Adriamycin,
and etoposide) were shown to cause muscle wasting
directly via activation of the NF-kB pathway and
independently of the commonly implicated ubiq-
uitin-proteasome system, or indirectly via produc-
tion of pro-inflammatory cytokines, such as IL-1b,
IL-6, and TNF, or by inducing oxidative stress and
tissue injury [55–57]. Other independent investiga-
tions also proposed that the molecular mechanisms
accounting for the loss of muscle size and strength
in animals bearing cancer and/or exposed to che-
motherapy were correlated with activation of pro-
inflammatory pathways, down-regulation of anab-
olism and exacerbation of muscle proteolysis [58].
In the attempt to identify some of the mecha-
nisms responsible for the development of cachexia
following exposure to chemotherapy, we recently
investigated the role of some of the anticancer agents
utilized for the treatmentof colorectal andother solid
tumors, namely FOLFIRI (5-FU, leucovorin, irinote-
can) and FOLFOX (5-FU, leucovorin, oxaliplatin) [9].
The administration of these widely used chemother-
apy regimens to healthy mice was able to reproduce
some of the alterations typical of cancer cachexia,
including body weight loss, adipose tissue, skeletal
musclewasting, andweakness. Our evidence showed
that the chemotherapy treatmentwas responsible for
hyperactivation of the ERK1/2 signaling pathway,
previously involved in the pathogenesis of cachexia
[59], as well as for structural changes in the sarco-
meres and for dramatic muscle mitochondrial deple-
tion. Chemotherapy also led to abnormal oxidative
metabolism and to an oxidative-to-glycolytic shift in
fiber type composition [9].
Interestingly, these findings were in line with
previously published data, suggesting that cancer
and chemotherapy may promote the appearance of
a cachectic phenotype by activating similar mecha-
nisms [60]. Our observations were also subsequently
validated by our comprehensive proteomic profiling
aimed at comparing cachexia in a setting of cancerVolume 12  Number 4  December 2018
Preservation of muscle mass in cancer chemotherapy Pin et al.or following chemotherapy [61]. Importantly, tra-
becular bone tissue was also significantly affected by
chemotherapy treatments. For instance, doxorubi-
cin and, in particular, FOLFIRI were recently shown
to promote dramatic loss of bone [62,63
&
], whereas
aromatase inhibitors, usually prescribed as the stan-
dard of care in the therapy of postmenopausal breast
cancer, were shown to promote osteolysis by acti-
vating osteoclast-mediated bone resorption and to
exacerbate muscle weakness in animals bearing
estrogen-receptor negative breast cancers [64]. Alto-
gether, these findings suggest that administration of
compounds with cytotoxic and antiproliferative
properties promote muscle and bone derangements
by activating a wide range of mechanisms.PRESERVATION OF MUSCLE MASS AS A
TOOL TO COUNTERACT CHEMOTHERAPY
TOXICITY
Experimental and clinical data support the impor-
tance of the relationship between muscle mass andFIGURE 1. Pro-anabolic strategies preserve muscle mass in as
usually responsible for derangements of skeletal muscle size and
improve quality of life and survival in cancer patients.
1751-4258 Copyright  2018 The Author(s). Published by Wolters Kluwethe response to chemotherapy, thus also suggesting
that preservation of muscle mass per se represents a
novel strategy to ultimately prevent chemotherapy
toxicity and improve quality of life with cancer.
Agents targeting skeletal muscle anabolism have
been tested with the goal of preservingmuscle mass
in the presence of cancer and following the treat-
ment with chemotherapy drugs (Fig. 1). In 2008,
Garcia et al. [65] proposed the treatment with
ghrelin, a potent growth hormone secretagogue
endowed with orexigenic and neuroprotective
properties, as a method to counteract cisplatin-
associated loss of body and muscle weight. The
molecular mechanisms involved in determining
better muscle phenotype and improved survival
in tumor hosts exposed to chemotherapy included
down-regulation of inflammation and p38/C/EBP-
b/myostatin signaling, as well as activation of Akt
and myogenic factors, such as myogenin, and
myoD [58]. Another group showed that synthetic
agonists of the ghrelin receptor counteract chemo-
therapy-induced toxicity by effectively preventingsociation with chemotherapy. Counteraction of mechanisms
function contributes to reduce chemotherapy toxicity and to
r Health, Inc. www.supportiveandpalliativecare.com 423
Cachexia, nutrition and hydrationcalcium dysregulation and mitochondrial damage
in skeletal muscle [66,67].
With others, we reported that ACVR2B/Fc
potently counteracts muscle wasting in combina-
tion with FOLFIRI [63
&
], doxorubicin [62], or cis-
platin [68
&
]. ACVR2B/Fc is a soluble ACVR2B fusion
protein and inhibitor of the activin 2B receptor
signaling previously shown to preserve muscle mass
and prolong better survival in tumor hosts [69].
Interestingly, our recent studies found that
ACVR2B/Fc also exerts powerful protective effects
related to the preservation of bone mass in animals
chronically administered FOLFIRI in combination
with ACVR2B/Fc. These findings further demon-
strate that the preservation of muscle mass may
provide a tool to counteract chemotherapy toxicity
by identifying a potential strategy for the detection
of early cancer-associated musculoskeletal deficits
following cancer treatments [63
&
].CONCLUSION
Changes in body composition, mainly resulting in
depletion of skeletal muscle mass, have been linked
to the use of anticancer drugs. On the basis of a
growing number of experimental and clinical stud-
ies, there is now substantial agreement on the idea
that the loss of lean mass represents an accurate
prognostic factor for augmented treatment toxicity,
worsened outcomes, and overall reduced survival in
cancer patients. In an attempt to identify themolec-
ular causes responsible formusculoskeletal disorders
upon treatment with chemotherapy, several
research groups have focused their attention on
the in-vivo effects of commonly used chemotherapy
regimens, including cisplatin, doxorubicin, FOL-
FIRI. These findings support that muscle size and
function are primarily affected by activating signal-
ing pathways that have been previously implicated
in promoting muscle atrophy and that are driven by
processes that impinge on mitochondrial metabo-
lism and muscle protein homeostasis. A series of
promising experimental data also suggests the use of
muscle pro-anabolic strategies as powerful tools to
spare lean tissue in a setting of cancer or chemother-
apy (Fig. 1). However, additional studies are neces-
sary to establish novel methods for the accurate
assessment of body composition in patients with
cancer, with the ultimate goal of monitoring the
changes in fat, muscle, and bone tissue that follow
the treatment with chemotherapy. Completion of
this endeavor will ultimately allow performing
simultaneous adjustment of drug dosing, thus also
attaining reduction in musculoskeletal side effects
in patients with cancer.424 www.supportiveandpalliativecare.comAcknowledgements
The authors would like to thank ‘Servier Medical Art’ (Les
Laboratoires Servier, Suresne, France) for providing free
access to their medical images, and John P. Spence, PhD
for his precious contribution in editing the manuscript.
Financial support and sponsorship
This study was supported by the Department of Surgery
and the Department of Otolaryngology – Head & Neck
Surgery at Indiana University, and by grants to A.B. from
the V Foundation for Cancer Research (V2017-021), the
American Cancer Society (Research Scholar Grant
132013-RSG-18-010-01-CCG) and the Indiana Univer-
sity Simon Cancer Center (IUSCC Associate Member
Pilot Funding Mechanism).
Conflicts of interest
There are no conflicts of interest.REFERENCES AND RECOMMENDED
READING
Papers of particular interest, published within the annual period of review, have
been highlighted as:
& of special interest
&& of outstanding interest1. Crawford S. Is it time for a new paradigm for systemic cancer treatment?
Lessons from a century of cancer chemotherapy. Front Pharmacol 2013;
4:68.
2. Brown DJ, McMillan DC, Milroy R. The correlation between fatigue, physical
function, the systemic inflammatory response, and psychological distress in
patients with advanced lung cancer. Cancer 2005; 103:377–382.
3. Galvao DA, Taaffe DR, Spry N, et al. Reduced muscle strength and functional
performance in men with prostate cancer undergoing androgen suppression:
a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis
2009; 12:198–203.
4. Hayes S, Battistutta D, Newman B. Objective and subjective upper body
function six months following diagnosis of breast cancer. Breast Cancer Res
Treat 2005; 94:1–10.
5. Knobel H, Havard Loge J, Lund MB, et al. Late medical complications and
fatigue in Hodgkin’s disease survivors. J Clin Oncol 2001; 19:3226–3233.
6. Luctkar-Flude M, Groll D,Woodend K, Tranmer J. Fatigue and physical activity
in older patients with cancer: a six-month follow-up study. Oncol Nurs Forum
2009; 36:194–202.
7. Meeske K, Smith AW, Alfano CM, et al. Fatigue in breast cancer survivors two
to five years post diagnosis: a HEAL Study report. Qual Life Res 2007;
16:947–960.
8. Goedendorp MM, Andrykowski MA, Donovan KA, et al. Prolonged impact of
chemotherapy on fatigue in breast cancer survivors: a longitudinal comparison
with radiotherapy-treated breast cancer survivors and noncancer controls.
Cancer 2012; 118:3833–3841.
9. Barreto R, Waning DL, Gao H, et al. Chemotherapy-related cachexia is
associated with mitochondrial depletion and the activation of ERK1/2 and
p38 MAPKs. Oncotarget 2016; 7:43442–43460.
10. Rosenthal MA, Oratz R. Phase II clinical trial of recombinant alpha 2b
interferon and 13 cis retinoic acid in patients with metastatic melanoma.
Am J Clin Oncol 1998; 21:352–354.
11. Visovsky C, Schneider SM. Cancer-related fatigue. Online J Issues Nurs
2003; 8:8.
12. Cleeland CS, Allen JD, Roberts SA, et al. Reducing the toxicity of cancer
therapy: recognizing needs, taking action. Nat Rev Clin Oncol 2012;
9:471–478.
13. Dantzer R, Meagher MW, Cleeland CS. Translational approaches to treat-
ment-induced symptoms in cancer patients. Nat Rev Clin Oncol 2012;
9:414–426.
14. Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the
lives of patients: new findings from the fatigue coalition. Oncologist 2000;
5:353–360.
15. Glaus A. Assessment of fatigue in cancer and noncancer patients and in
healthy individuals. Support Care Cancer 1993; 1:305–315.Volume 12  Number 4  December 2018
Preservation of muscle mass in cancer chemotherapy Pin et al.16. Ahlberg K, Ekman T, Gaston-Johansson F, Mock V. Assessment and
management of cancer-related fatigue in adults. Lancet 2003; 362:
640–650.
17. Stasi R, Abriani L, Beccaglia P, et al. Cancer-related fatigue: evolving
concepts in evaluation and treatment. Cancer 2003; 98:1786–1801.
18.
&&
Neefjes ECW, van den Hurk RM, Blauwhoff-Buskermolen S, et al. Muscle
mass as a target to reduce fatigue in patients with advanced cancer.
J Cachexia Sarcopenia Muscle 2017; 8:623–629.
This article describes the association between changes in skeletal muscle index
(SMI) and cancer-related fatigue (CRF) in male cancer patients undergoing
palliative chemotherapy, therefore, suggesting that CRF can be reduced by
exercise interventions that may concurrently increase muscle mass.
19. Patrick DL, Ferketich SL, Frame PS, et al. National Institutes of Health State-
of-the-Science Conference Statement: Symptom management in cancer:
pain, depression, and fatigue, July 15–17, 2002. J Natl Cancer Inst Monogr
2004; 9–16.
20. NHLBI Workshop summary. Respiratory muscle fatigue. Report of the Re-
spiratory Muscle Fatigue Workshop Group. Am Rev Respir Dis 1990;
142:474–480.
21. Jacobsen PB, Donovan KA, Small BJ, et al. Fatigue after treatment for early
stage breast cancer: a controlled comparison. Cancer 2007; 110:
1851–1859.
22. Prue G, Allen J, Gracey J, et al. Fatigue in gynecological cancer patients
during and after anticancer treatment. J Pain Symptom Manage 2010;
39:197–210.
23. Cella D, Peterman A, Passik S, et al. Progress toward guidelines for the
management of fatigue. Oncology (Williston Park) 1998; 12:369–377.
24. Jacobsen PB, Hann DM, Azzarello LM, et al. Fatigue in women receiving
adjuvant chemotherapy for breast cancer: characteristics, course, and corre-
lates. J Pain Symptom Manage 1999; 18:233–242.
25. Nail LM. Fatigue in patients with cancer. Oncol Nurs Forum 2002; 29:537.
26. Mock V, Pickett M, Ropka ME, et al. Fatigue and quality of life outcomes of
exercise during cancer treatment. Cancer Pract 2001; 9:119–127.
27. Montazeri A. Quality of life data as prognostic indicators of survival in cancer
patients: an overview of the literature from 1982 to 2008. Health Qual Life
Outcomes 2009; 7:102.
28.
&
Klassen O, Schmidt ME, Ulrich CM, et al. Muscle strength in breast cancer
patients receiving different treatment regimes. J Cachexia Sarcopenia Muscle
2017; 8:305–316.
This study provides evidence that muscle functional alterations, frequently asso-
ciated with chemotherapy treatments, can appear before muscle atrophy becomes
evident.
29. Naito T, Okayama T, Aoyama T, et al. Skeletal muscle depletion during
chemotherapy has a large impact on physical function in elderly Japanese
patients with advanced nonsmall-cell lung cancer. BMC cancer 2017;
17:571.
30. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if
height and weight be known. 1916. Nutrition 1989; 5:303–311.
31. Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs:
the good, the bad and body-surface area. Eur J Cancer 2002; 38:
1677–1684.
32. Ratain MJ. Body-surface area as a basis for dosing of anticancer agents:
science, myth, or habit? J Clin Oncol 1998; 16:2297–2298.
33. Thoresen L, Frykholm G, Lydersen S, et al. Nutritional status, cachexia and
survival in patients with advanced colorectal carcinoma. Different assessment
criteria for nutritional status provide unequal results. Clin Nutr 2013;
32:65–72.
34. Chatelut E, White-Koning ML, Mathijssen RH, et al. Dose banding as an
alternative to body surface area-based dosing of chemotherapeutic agents.
Br J Cancer 2012; 107:1100–1106.
35. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications
of sarcopenic obesity in patients with solid tumours of the respiratory and
gastrointestinal tracts: a population-based study. Lancet Oncol 2008;
9:629–635.
36. Prado CM, Baracos VE, McCargar LJ, et al. Body composition as an
independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin
Cancer Res 2007; 13:3264–3268.
37. Antoun S, Baracos VE, Birdsell L, et al. Low body mass index and sarcopenia
associated with dose-limiting toxicity of sorafenib in patients with renal cell
carcinoma. Ann Oncol 2010; 21:1594–1598.
38. Rier HN, Jager A, Sleijfer S, et al. The prevalence and prognostic value of low
muscle mass in cancer patients: a review of the literature. Oncologist 2016;
21:1396–1409.
39. Sandini M, Bernasconi DP, Fior D, et al. A high visceral adipose tissue-to-
skeletal muscle ratio as a determinant of major complications after pancrea-
toduodenectomy for cancer. Nutrition 2016; 32:1231–1237.
40.
&&
Ali R, Baracos VE, Sawyer MB, et al. Lean body mass as an independent
determinant of dose-limiting toxicity and neuropathy in patients with colon
cancer treated with FOLFOX regimens. Cancer Med 2016; 5:607–616.
The data reported in this study aim at determining whether changes in lean body
mass (LBM) correlate with dose-limiting toxicity in patients with colon cancer
treated with FOLFOX. The conclusions show that low LBM is a significant
predictor of toxicity and neuropathy in patients administered FOLFOX-based
regimens using conventional body surface area dosing.1751-4258 Copyright  2018 The Author(s). Published by Wolters Kluwe41. Martin L, Birdsell L, Macdonald N, et al.Cancer cachexia in the age of obesity:
skeletal muscle depletion is a powerful prognostic factor, independent of
body mass index. J Clin Oncology 2013; 31:1539–1547.
42. Baracos VE, Arribas L. Sarcopenic obesity: hidden muscle wasting and its
impact for survival and complications of cancer therapy. Ann Oncol 2018;
29(Suppl 2):ii1–ii9.
43. Anandavadivelan P, Brismar TB, Nilsson M, et al. Sarcopenic obesity: a
probable risk factor for dose limiting toxicity during neo-adjuvant chemother-
apy in oesophageal cancer patients. Clin Nutr 2016; 35:724–730.
44. Miyamoto Y, Oki E, Emi Y, et al. Low visceral fat content is a negative
predictive marker for bevacizumab in metastatic colorectal cancer. Anticancer
Res 2018; 38:491–499.
45. Cespedes Feliciano EM, Lee VS, Prado CM, et al. Muscle mass at the time of
diagnosis of nonmetastatic colon cancer and early discontinuation of che-
motherapy, delays, and dose reductions on adjuvant FOLFOX: the C-SCANS
study. Cancer 2017; 123:4868–4877.
46. Miyamoto Y, Baba Y, Sakamoto Y, et al. Sarcopenia is a negative prognostic
factor after curative resection of colorectal cancer. Ann Surg Oncol 2015;
22:2663–2668.
47.
&
Blauwhoff-Buskermolen S, Versteeg KS, de van der Schueren MA, et al. Loss
of muscle mass during chemotherapy is predictive for poor survival of patients
with metastatic colorectal cancer. J Clin Oncol 2016; 34:1339–1344.
This is an important study showing that muscle size is significantly affected during
chemotherapy and represents an independent predictor of survival in patients with
metastatic colorectal cancer (mCRC).
48. Chu MP, Lieffers J, Ghosh S, et al. Skeletal muscle density is an independent
predictor of diffuse large B-cell lymphoma outcomes treated with rituximab-
based chemoimmunotherapy. J Cachexia Sarcopenia Muscle 2017;
8:298–304.
49. Daly LE, Ni Bhuachalla EB, Power DG, et al. Loss of skeletal muscle during
systemic chemotherapy is prognostic of poor survival in patients with foregut
cancer. J Cachexia Sarcopenia Muscle 2018; 9:315–325.
50. Rutten IJG, van Dijk DPJ, Kruitwagen RFPM, et al. Loss of skeletal muscle
during neoadjuvant chemotherapy is related to decreased survival in ovarian
cancer patients. J Cachexia Sarcopenia Muscle 2016; 7:458–466.
51. Nattenmuller J, Wochner R, Muley T, et al. Prognostic impact of CT-quantified
muscle and fat distribution before and after first-line-chemotherapy in lung
cancer patients. PloS One 2017; 12:e0169136.
52. Patel JD, Pereira JR, Chen J, et al. Relationship between efficacy outcomes
and weight gain during treatment of advanced, nonsquamous, nonsmall-cell
lung cancer patients. Ann Oncol 2016; 27:1612–1619.
53.
&
Sandini M, Patino M, Ferrone CR, et al. Association between changes in body
composition and neoadjuvant treatment for pancreatic cancer. JAMA Surg
2018. [Epub ahead of print]
In this article, the gain in muscle mass following neoadjuvant treatments positively
correlates with increased success of tumor resection and overall survival in
pancreatic cancer patients.
54. Le Bricon T, Gugins S, Cynober L, Baracos VE. Negative impact of cancer
chemotherapy on protein metabolism in healthy and tumor-bearing rats.
Metabolism 1995; 44:1340–1348.
55. Sultani M, Stringer AM, Bowen JM, Gibson RJ. Anti-inflammatory cytokines:
important immunoregulatory factors contributing to chemotherapy-induced
gastrointestinal mucositis. Chemother Res Pract 2012; 2012:490804.
56. Damrauer JS, Stadler ME, Acharyya S, et al. Chemotherapy-induced muscle
wasting: association with NF-kB and cancer cachexia. Basic Appl Myol 2008;
18:139–148.
57. Gilliam LA, St Clair DK. Chemotherapy-induced weakness and fatigue in
skeletal muscle: the role of oxidative stress. Antioxid Redox Signal 2011;
15:2543–2563.
58. Chen JA, Splenser A, Guillory B, et al. Ghrelin prevents tumour- and cisplatin-
induced muscle wasting: characterization of multiple mechanisms involved.
J Cachexia Sarcopenia Muscle 2015; 6:132–143.
59. Penna F, Costamagna D, Fanzani A, et al. Muscle wasting and impaired
myogenesis in tumor bearing mice are prevented by ERK inhibition. PloS One
2010; 5:e13604.
60. Pin F, Busquets S, Toledo M, et al. Combination of exercise training and
erythropoietin prevents cancer-induced muscle alterations. Oncotarget
2015; 6:43202–43215.
61. Barreto R, Mandili G, Witzmann FA, et al. Cancer and chemotherapy con-
tribute to muscle loss by activating common signaling pathways. Front Physiol
2016; 7:472.
62. Nissinen TA, Degerman J, Rasanen M, et al. Systemic blockade of ACVR2B
ligands prevents chemotherapy-induced muscle wasting by restoring muscle
protein synthesis without affecting oxidative capacity or atrogenes. Sci Rep
2016; 6:32695.
63.
&
Barreto R, Kitase Y, Matsumoto T, et al. ACVR2B/Fc counteracts chemother-
apy-induced loss of muscle and bone mass. Sci Rep 2017; 7:14470.
This study reports bone loss as consequence of chronic administration of antic-
ancer drugs and shows that pro-anabolic strategies may reduce the occurrence of
musculoskeletal defects following chemotherapy.
64. Wright LE, Harhash AA, KozlowWM, et al. Aromatase inhibitor-induced bone
loss increases the progression of estrogen receptor-negative breast cancer
in bone and exacerbates muscle weakness in vivo. Oncotarget 2017;
8:8406–8419.r Health, Inc. www.supportiveandpalliativecare.com 425
Cachexia, nutrition and hydration65. Garcia JM, Cata JP, Dougherty PM, Smith RG.Ghrelin prevents cisplatin-induced
mechanical hyperalgesia and cachexia. Endocrinology 2008; 149:455–460.
66. Sirago G, Conte E, Fracasso F, et al. Growth hormone secretagogues
hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages
in a rat model of cisplatin-induced cachexia. Sci Rep 2017; 7:13017.
67. Conte E, Camerino GM, Mele A, et al. Growth hormone secretagogues
prevent dysregulation of skeletal muscle calcium homeostasis in a rat model
of cisplatin-induced cachexia. J Cachexia Sarcopenia Muscle 2017;
8:386–404.426 www.supportiveandpalliativecare.com68.
&
Hatakeyama S, Summermatter S, Jourdain M, et al. ActRII blockade protects
mice from cancer cachexia and prolongs survival in the presence of anticancer
treatments. Skelet Muscle 2016; 6:26.
This was the first study to suggest the use of ActRII blockade for the preservation
of muscle mass and the reduction of muscle toxicities in the presence of anticancer
therapies.
69. Benny Klimek ME, Aydogdu T, Link MJ, et al. Acute inhibition of myostatin-
family proteins preserves skeletal muscle in mouse models of cancer cachex-
ia. Biochem Biophys Res Commun 2010; 391:1548–1554.Volume 12  Number 4  December 2018
